

Acute effects of coffee on endothelial function and glucose metabolism in healthy volunteers

Submission date
31/10/2007

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
06/11/2007

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
04/06/2019

Condition category
Nutritional, Metabolic, Endocrine

☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Silvio Buscemi

Contact details
Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefrourologiche
Via del Vespro, 129
Palermo
Italy
90127

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
02/2007

Study information

Scientific Title

Acute effects of coffee on endothelial function and glucose metabolism in healthy volunteers

Study objectives

Please note that as of 15/05/2008 this trial record was extensively amended. Most of the changes to this record can be found in the relevant field, under the date on which the amendment was made. The following changes have also taken place:

1. The total number of participants has been amended from 20 to 50
2. Only 20 of the 50 participants were assessed for all primary and secondary outcome measures, whereas the remaining 30 participants were assessed only for the QTc intervals (secondary outcome field no. 3). Please see Primary/Secondary outcome measures field for detail.

Study hypothesis:

Caffeine or unknown components of coffee might acutely influence endothelial function as well as glucose metabolism.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Local Ethical Committee of the University Hospital of Palermo (I) on the 3rd October 2007 (ref: 09/07).

Study design

Randomised, crossed, double-blind, placebo controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Cardiovascular and metabolic diseases

Interventions

Participants will receive on two occasions with a random and blind order respectively a cup of caffeinated coffee and a cup of decaffeinated coffee (a standardised cup of 25 ml Italian espresso) with a one week interval. The two beverages are obtained by the same mixture of coffee and they differ only for their caffeine content.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Caffeine

Primary outcome measure

Amendment as of 15/05/2008: Please note that the primary outcome measure was assessed in only 20 participants.

Acute effects of both coffees (caffeinated and decaffeinated) on endothelial function, measured as "Flow Mediated Dilation", and on glucose metabolism, as blood concentrations of glucose, insulin and c-peptide, will be measured in each occasion before, 30 and 60 minutes after coffee ingestion.

Secondary outcome measures

Amendment as of 15/05/2008: Please note that all secondary outcome measures were assessed in only 20 participants, except the QTc interval measurement (no. 3 below), which was carried out for all participants.

1. Intra-renal haemodynamic measurements (resistance and pulsatility indexes), obtained before and 60 minutes after coffee ingestion in both occasions
2. Blood pressure, obtained before and 60 minutes after coffee ingestion in both occasions
3. Electrocardiogram with QTc interval measurement, obtained before and 60 minutes after coffee ingestion in both occasions
4. A blood sample will be collected before and 60 minutes after coffee ingestion in both occasions and the serum samples will be frozen at -80°C for measurement of some cytokines (Interleukin-6 [IL-6], Tumour Necrotising Factor [TNF]-alpha, etc.)

Overall study start date

01/10/2007

Completion date

15/12/2007

Eligibility**Key inclusion criteria**

1. Male and female healthy subjects
2. Range of age: 25 - 50 years
3. Range of Body Mass Index (BMI): 20 - 28 kg/m²

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

50

Total final enrolment

20

Key exclusion criteria

1. Any metabolic, cardiovascular or systemic disease
2. Any drug treatment
3. Smoking habits
4. Pregnancy or lactation in the last six months

Date of first enrolment

01/10/2007

Date of final enrolment

15/12/2007

Locations

Countries of recruitment

Italy

Study participating centre

Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefrourologiche

Palermo

Italy

90127

Sponsor information

Organisation

University of Palermo (Italy)

Sponsor details

Piazza Marina

Palermo

Italy

90100

Sponsor type

University/education

Website

<http://www.unipa.it>

ROR

<https://ror.org/044k9ta02>

Funder(s)

Funder type

Government

Funder Name

Italian Ministry of the University of Scientific and Technological Research (Ministero Dell'università E Della Ricerca Scientifica E Tectnologica [MURST]) (Italy)

Funder Name

Coffee to be tested is offered by Morettino s.p.a. Palermo (Italy)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2010	04/06/2019	Yes	No